Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Biocartis  /  Biocartis forum geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Biocartis BRU:BCART.BL, BE0974281132

  • 0,290 22 sep 2023
  • 0,000 (0,00%) Dagrange 0,000 - 0,000
  • 0

Biocartis forum geopend

6.451 Posts
Pagina: «« 1 ... 238 239 240 241 242 ... 323 »» | Laatste | Omlaag ↓
  7. Bonsjoer 15 september 2021 20:21
    quote:

    ElTorro schreef op 15 september 2021 18:29:

    Thanks. Ik neem aan dat jouw order nog niet is uitgevoerd.
    Idd., mijn positie in Biocartis is momenteel 0 , morgen maar weer eens kijken. Als er morgenochtend een PB komt met positief nieuws dat eindelijk de M2 lijn weer draait en voldoende grondstoffen beschikbaar zijn dan zal ik, voorlopig, wel 'te laat ' zijn.., zoniet., dan zakken we morgen wellicht verder de diepte in.
  9. Flatlander 17 september 2021 04:22
    quote:

    ElTorro schreef op 16 september 2021 22:09:

    FL, what's happening with Novacyt, back from where they started. Also one setback after the other it seems..
    El Torro

    I think two things are weighing on NVCT. 1) They just took a 40.1 million pound charge off against H1 revenues. This writes off the entirety of the DHSC dispute, yet they continue to continue to go thru arbitration/mediation, so the matter is far from dead or resolved. They very well may have a windfall down the road. I think the UK government created an overhang that they could use to dissuade potential acquirers from gobbling up NYCT during the pandemic since accurate PCR testing was deemed a strategic national importance.

    The 2nd thing weighing the company down is that they have yet to unveil their post pandemic plan in any detail. Many seem to feel that the pandemic will soon be in the rear view mirror. Meanwhile the company trades for less than 2x the cash in the bank and the PE is about 1.7. Pretty pathetic.

    NVCT has no debt and may have 200 million EU in the bank by year end. They are looking for acquisitions and they have considerable PCR reagents. If BCART doesn't restart full operations on ML2 soon, they could be vulnerable to a takeover deal for cash & reagents. Mostly joking.

    I'm finding productive grounds for speculation in Canada. My position in BCART has been reduced, but I still planning on 2022 being a final decision year. They need to right the ship and hit on some of the milestones they have been touting for years.

    FL
  10. ElTorro 17 september 2021 09:28
    FL, I hope we can discuss soon on some positive topics. I'm holding my position for now and sweating out this period of incertitude. October is nearing and they have to come up with any kind of communication concerning the reagents and ML2. The longer this takes, the more it looks like this news will not be that great (hope I'm wrong).. or again a half full/empty glass story which I don't like either.
  14. JotieP 21 september 2021 10:17
    I keep getting the same tweets from Biocartis. every tweet is relaunched a couple of days later. Since 2 sept, i got 4 times the same tweet about the very good figures of H1 2021 (which were actually not really good in my point of view. It's easy to have huge improvements if you are comparing with the figures from the lockdown).
    I would recommend Biocartis to put their very eager and motivated PR employee in the sales team. go go go!
  15. JotieP 21 september 2021 10:18
    @21nov: restart ML2 was planned end of september (PR 17 aug). This was later rescheduled to "second half of september" (PR 02 sept).
    I don't mind that we did not get an update yet. I prefer the update at end of month "we are live again with ML2" above an update now "we expect to go live in a week with ML2". I'm a bit tired with biocartis settings goals and not achieving them for various reasons, so i would only get nervous about biocartis talking about something to happen in the future :-) .
  18. JotieP 21 september 2021 13:35
    @21nov: as long as they are selling the cartridges only slightly above COGS, they will never be profitable. unfortunately, due to the fire, H2 2021 figures will be polluted again. COGS will be higher due to production on first line instead of ML2. so first time we could see the real COGS will be H1 2022 figures ... that's in a year.

    unfortunatly, BCART is squeezed due to cashburn AND convertible loans.
    convertible loans are due 9 may 2024. If the stock price is by then not higher than 12.9, BCART will probably have to pay-out the remaining 135Mio.
    unfortunatly, the cash is currently 85Mio and the cashburn is 30-40Mio each half year. Let's say that at this rate, BCART is out of money end 2022.

    A capital raise is inevitable. It would be great if this is done shortly after presenting great figures. Due to the fire, we can say H2 2021 will not be great. fingers crossed then for H1 2022, as this will be the last chance.

    I must say i would be more comfortable with a lower position in BCART. I would however not sell it all. I strongly believe in the technology and if they manage to turn tides (finally), then my big loss might turn into a big profit. Currently that's just one big question mark.

    being an altruist, i wish you all a huge increase in stockprice!
  19. Flatlander 21 september 2021 15:19
    quote:

    JotieP schreef op 21 september 2021 13:35:

    @21nov: as long as they are selling the cartridges only slightly above COGS, they will never be profitable. unfortunately, due to the fire, H2 2021 figures will be polluted again. COGS will be higher due to production on first line instead of ML2. so first time we could see the real COGS will be H1 2022 figures ... that's in a year.

    unfortunatly, BCART is squeezed due to cashburn AND convertible loans.
    convertible loans are due 9 may 2024. If the stock price is by then not higher than 12.9, BCART will probably have to pay-out the remaining 135Mio.
    unfortunatly, the cash is currently 85Mio and the cashburn is 30-40Mio each half year. Let's say that at this rate, BCART is out of money end 2022.

    A capital raise is inevitable. It would be great if this is done shortly after presenting great figures. Due to the fire, we can say H2 2021 will not be great. fingers crossed then for H1 2022, as this will be the last chance.

    I must say i would be more comfortable with a lower position in BCART. I would however not sell it all. I strongly believe in the technology and if they manage to turn tides (finally), then my big loss might turn into a big profit. Currently that's just one big question mark.

    being an altruist, i wish you all a huge increase in stockprice!
    JotieP
    As I have said in many posts, the pandemic creates demand for the type of automation that Idylla offers. Unfortunately, BCART can no longer meet this demand because the supply is constrained. Verrest sees profitability in 2 to 3 years. I kind of recall him making a similar statement a couple years ago, so it is hard to place much significance on the statement.

    During the 1st half, I was really looking for any evidence that margins were improving and the loss gap was shrinking. They failed to deliver on those metrics. Yet, it is hard to walk away since they are still limited in the US by the lack of IVD registrations and the RUI designation.

    Life is funny sometimes. I own a small cap biopharma CRVS that i have held for about a year. I love the science and the management has a phenomenal record of creating shareholder value with their history of previous pharma ventures. However, they terminated their Phase 3 trial on a COVID treatment and their next pipeline drug was just entering phase 2 and was years away from possible commercialization. So there appeared to be no immediate catalysts. Long story short , last week AZN and their partner released a study at ESMO showing that a combination drug that included an CD-73 inhibitor (very similar to CRVS drug) significantly increased PFS. CRVS is up about 150% in 2 days since the ESMO presentation. In the weeks leading up to the runup I had debated selling out since there were no apparent catalysts. BCART appears to have all kinds of potential catalysts yet they always seem to fail to capitalize. Instead they find a way to kick the can down the road! Ultimately, my CRVS story is meant to stress the importance of quality management. Verrest has yet to prove that he is overseeing a quality management team!

    FL
  20. Flatlander 22 september 2021 15:46
    Has there been a definitive report on the origins of the fire? In the US the fire marshal generally issues a statement regarding the origin of a fire (electrical, careless smoking, lightning etc.). At the very least the origins will be declared suspicious or occasionally unknown. I don't want to be too suspicious but would like to hear that arson or industrial sabotage have been ruled out and that a likely source has been identified and corrected.

    FL
6.451 Posts
Pagina: «« 1 ... 238 239 240 241 242 ... 323 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!